Wave Life Sciences director exercises and sells 7,000 shares

Wave Life Sciences director Heidi L. Wagner exercised options for 7,000 ordinary shares at an exercise price of $5.97 per share on August 11, 2026, and sold the resulting 7,000 shares of common stock at $6.01 per share.

Rhea-AI Filing Summary

Wave Life Sciences director Heidi L. Wagner exercised options for 7,000 ordinary shares at an exercise price of $5.97 per share on August 11, 2026, and sold the resulting 7,000 shares of common stock at $6.01 per share. The derivative position reported from this option grant was reduced to 0 following the transaction. The company notes these fully vested option exercises and related sale were effected pursuant to a Rule 10b5-1 trading plan adopted on March 6, 2026.

Insider Trade Summary 10b5-1

Exercise and sale activity reported; no spread calculated

Exercise and Sale 3 txns

Insider Wagner Heidi L

Role Director

Sold 7,000 shs ($42K)

Approx. gross sale proceeds $42K

Approx. exercise cost $42K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy) F1, F2	7,000	$0.00	$0.00
Exercise	Common Stock F1	7,000	$5.97	$42K
Sale	Common Stock F1	7,000	$6.01	$42K

Holdings After Transaction: Stock Option (right to buy) — 0 contracts (Direct); Common Stock — 44,930 shares (Direct)

Footnotes (2)

1. F1. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.
2. F2. These stock options are fully vested.

Key Figures

Options exercised: 7,000 shares Option exercise price: $5.97 per share Shares sold: 7,000 shares +4 more

7 metrics

Options exercised 7,000 shares Stock Option (right to buy) exercised on August 11, 2026

Option exercise price $5.97 per share Conversion or exercise price of stock options exercised

Shares sold 7,000 shares Common Stock sale on August 11, 2026

Sale price $6.01 per share Price for Common Stock sale transaction

Options remaining from grant 0 options Total derivative shares following option exercise transaction

Rule 10b5-1 plan adoption date March 6, 2026 Date the reporting person adopted the trading plan

Option expiration date August 16, 2026 Scheduled expiration date of the exercised stock options

Key Terms

Rule 10b5-1 trading plan, Stock Option (right to buy, Exercise or conversion of derivative security, Redomiciliation, +1 more

5 terms

Rule 10b5-1 trading plan regulatory

"were effected pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

Stock Option (right to buy financial

"security_title": "Stock Option (right to buy)""

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

Redomiciliation regulatory

"The Redomiciliation had the effect of changing Wave-Singapore's domicile"

Redomiciliation is when a company legally changes its country of incorporation while keeping the same business and assets, like moving a house to a new neighborhood but keeping the same furniture. Investors care because the company then follows a different set of laws and tax rules, which can change shareholder rights, reporting standards, dividend treatment and the ease of trading the stock, potentially affecting risk and return.

Ordinary Shares financial

"underlying_security_title": "Ordinary Shares""

Ordinary shares are a type of ownership stake in a company, giving shareholders a right to participate in the company’s profits and decision-making through voting. They are similar to owning a piece of a business, and their value can rise or fall based on the company's performance. Investors buy ordinary shares to potentially earn dividends and benefit from the company's growth over time.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did Wave Life Sciences (WVE) director Heidi L. Wagner do in this Form 4?

Heidi L. Wagner exercised 7,000 stock options at $5.97 per share and sold 7,000 common shares at $6.01 per share on August 11, 2026.

How many Wave Life Sciences (WVE) options did Heidi L. Wagner exercise and at what price?

She exercised 7,000 stock options with an exercise price of $5.97 per share. These options were fully vested, and the exercise converted them into 7,000 ordinary shares before the subsequent sale.

At what price were the Wave Life Sciences (WVE) shares sold by Heidi L. Wagner?

Heidi L. Wagner sold 7,000 common shares of Wave Life Sciences at a price of $6.01 per share on August 11, 2026, immediately following the option exercise.

Was the Wave Life Sciences (WVE) insider transaction under a Rule 10b5-1 plan?

Yes, the option exercise and share sale were carried out under a Rule 10b5-1 trading plan adopted by Heidi L. Wagner on March 6, 2026, indicating pre-arranged trading instructions.

What happened to Heidi L. Wagner’s Wave Life Sciences (WVE) options after this transaction?

After exercising the reported options, the derivative position from this option grant was reduced to 0 options remaining, as the 7,000 fully vested options were fully exercised and converted into common shares.

Did the Wave Life Sciences (WVE) redomiciliation affect this insider’s ownership proportion?

The company states the August 7, 2026 redomiciliation from Singapore to Delaware did not alter securityholders’ proportionate interests; shares were exchanged on a one-for-one basis into Wave Life Sciences, Inc. common stock.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 08/13/2026 - 09:00 PM Accepted by SEC EDGAR 08/13/2026 - 09:00 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Wagner Heidi L

(Last) (First) (Middle)

C/O WAVE LIFE SCIENCES, INC.,

733 CONCORD AVE.

(Street)

CAMBRIDGE MASSACHUSETTS 02138

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Wave Life Sciences, Inc. [ WVE ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/11/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/11/2026		M(1)		7,000	A	$5.97	51,930	D
Common Stock	08/11/2026		S(1)		7,000	D	$6.01	44,930	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$5.97	08/11/2026		M(1)			7,000	(2)	08/16/2026	Ordinary Shares	7,000	$0.00	0	D

Explanation of Responses:

1. The option exercise and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 6, 2026.

2. These stock options are fully vested.

Remarks:

On August 7, 2026, Wave Life Sciences, Inc., a Delaware corporation, became the successor of Wave Life Sciences Ltd., a company organized under the laws of the Republic of Singapore ("Wave-Singapore"), pursuant to a scheme of arrangement under Singapore law under which all issued ordinary shares in the capital of Wave-Singapore were exchanged on a one-for-one basis for shares of common stock of Wave Life Sciences, Inc. (the "Redomiciliation"). The Redomiciliation had the effect of changing Wave-Singapore's domicile, but did not alter the proportionate interests of securityholders. Exhibit 24.1 - Power of Attorney

	/s/ Heidi L. Wagner	08/13/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)